Tenapanor in Synucleinopathy-Related Constipation

Part of paid clinical trials in Waterloo, Iowa.

Sponsor
Cedar Valley Digestive Health Center
Study ID
NCT06460038
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

  • Tenapanor — DRUG
    Inhibitor of NHE3
  • Placebo — DRUG
    Placebo drug

Study Details

Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation

Key Dates

Start date
Jan 1, 2025
Status verified
Feb 2025
Primary completion
Dec 31, 2026
Completion
Mar 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Tenapanor
    Tenapanor 50 mg orally twice daily for 12 weeks
  • Placebo Comparator: Placebo
    Placebo orally twice daily for 12 weeks

Primary Outcome Measure

Complete spontaneous bowel movements (CSBM) [ Time Frame: 6 of 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cedar Valley Digestive Health CenterWaterlooIowa50701
Harichandana Punukula, PharmD, MS
[email protected]
319-888-8275

Find similar trials in Waterloo, IA

By condition
Parkinson's disease
By specialty
NeurologyBrain disorders
By research site
Cedar Valley Digestive Health Center· Waterloo, IA

Related Studies